SMAD3 and chronic kidney disease: A study reported that a novel long non-coding RNA (lncRNA) called Erbb4-IR is accountable for renal fibrosis that is mediated by TGF-β/Smad3, making it a selective therapeutic target for CKD (Feng et al., 2018).